Impilo to invest in Stille

Impilo has undertaken to subscribe for shares in a directed share issue carried out by Stille AB (publ). Impilo’s subscription undertaking, which corresponds to an investment amount of approximately SEK 220 million, is conditional upon e.g. an extraordinary general meeting of Stille approving the directed share issue, and Impilo’s investment being approved by the Inspectorate of Strategic Products (Sw. Inspektionen för strategiska produkter) in accordance with the Swedish Screening of Foreign Direct Investments Act (Sw. lagen (2023:560) om granskning av utländska direktinvesteringar).

Stille AB develops, manufactures and markets medical devices for surgeons across the world. Stille was founded in 1841 and is one of the world’s oldest medical device companies. Stille’s share is listed on Nasdaq First North Growth Market.

Impilo is a Nordic investment company focused on long-term investments in sustainable healthcare companies active in medical technology, pharmaceuticals, healthcare services, and other health-related areas.

Impilo is advised by Mannheimer Swartling in connection with the investment in Stille.


This website uses cookies to perform certain functions and help you navigate the site efficiently. A cookie is a text file with a small amount of information that is stored on your device. We share some of the information we obtain through these cookies with third parties. We only use cookies that are necessary for the site to function correctly and they therefore cannot be turned off. For further information, see Information on the use of cookies.